R&D channel feed

His tiny pre­na­tal test­ing com­pa­ny has big plans af­ter ex­act­ing le­gal re­venge on lab gi­ants

Last year
In Focus
Diagnostics

Day One Bio­phar­ma­ceu­ti­cals inks re­search col­lab­o­ra­tion with Swedish biotech

Last year
Deals

Im­pel Phar­ma con­sid­ers bank­rupt­cy, as­set sales de­spite mi­graine nasal spray quar­ter­ly rev­enue jump

Last year

Galec­to ax­es lead can­di­date in lung dis­ease af­ter PhI­Ib miss, stock craters

Last year

FDA lifts par­tial hold on Ar­cel­lx’s Gilead-part­nered blood can­cer cell ther­a­py as biotech aims for 2026 launch

Last year
Cell/Gene Tx

Ex­clu­sive: CSO George Yan­copou­los talks Re­gen­eron’s next chap­ter of ge­net­ics, weight loss drugs, and Alzheimer's

Last year
People

Fol­low­ing in­jec­tion side ef­fects, De­sign Ther­a­peu­tics to re­for­mu­late Friedre­ich's atax­ia drug, de­lay tri­al time­line

Last year

Alaunos’ run­way ends be­fore New Year's, as TCR biotech shrinks staff, seeks sale

Last year
People

Take­da spin­out Hill­e­Vax de­lays PhI­Ib norovirus topline da­ta un­til mid-2024 over pro­cess­ing lo­gis­tics

Last year

Fresh Tracks stops drug pipeline to save mon­ey as it keeps look­ing for an ex­it

Last year

Taysha rais­es $150M PIPE, shares sin­gle pa­tient da­ta on Rett syn­drome gene ther­a­py

Last year
Financing
Cell/Gene Tx

Af­ter pa­tient death, FDA slaps clin­i­cal hold on ear­ly-stage AML tri­al study­ing 2sev­en­ty bio as­set

Last year

BioX­cel lays off 100 em­ploy­ees as it looks to change up its strat­e­gy

Last year
People

Roivant CEO hints at more deals shap­ing up as key Im­muno­vant da­ta loom

Last year
Pharma

In­cyte ax­es blood can­cer col­lab with Sy­ros

Last year
Deals

Phar­ma com­pa­nies look to tap med­ical so­cial in­flu­encers in new agency part­ner­ship

Last year
Marketing

Drug­mak­ers pull back af­ter Covid boom, plan­ning to cut costs as they pre­pare for in­dus­try’s next era

Last year
Pharma
Coronavirus

ALX cuts two an­ti-CD47 pro­grams just weeks af­ter Gilead stopped a piv­otal study of its own can­di­date

Last year

New Alzheimer’s drug rais­es hopes — along with ques­tions

Last year

Hen­ri­et­ta Lack­s' fam­i­ly sues Ul­tragenyx over use of im­mor­tal HeLa cell line, claim­ing un­just en­rich­ment

Last year
Law

Atre­ca holds off de­vel­op­ment on its on­ly clin­i­cal pro­gram, cuts head­count by 40%

Last year
People

J&J re­ceives fifth FDA nod for treat­ing mul­ti­ple myelo­ma, with boxed warn­ing and REMS in tow

Last year
Pharma
FDA+

Ex­clu­sive: As­traZeneca’s out­go­ing R&D chief Mene Pan­ga­los re­flects on a 14-year R&D turn­around and the in­dus­try's fu­ture

Last year
People
Pharma

Il­lu­mi­na slash­es out­look for 2023, two ex­ec­u­tives de­part

Last year
First page Previous page 75767778798081 Next page Last page
A service from the Financial Times